Stockreport

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics, Inc.  (CADL) 
PDF Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival da [Read more]